ATE290879T1 - Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung - Google Patents

Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung

Info

Publication number
ATE290879T1
ATE290879T1 AT00957617T AT00957617T ATE290879T1 AT E290879 T1 ATE290879 T1 AT E290879T1 AT 00957617 T AT00957617 T AT 00957617T AT 00957617 T AT00957617 T AT 00957617T AT E290879 T1 ATE290879 T1 AT E290879T1
Authority
AT
Austria
Prior art keywords
muc
antigen
antibodies against
therapeutic antibodies
therapeutic compositions
Prior art date
Application number
AT00957617T
Other languages
German (de)
English (en)
Inventor
Ragupathy Madiyalakan
Original Assignee
Altarex Medical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altarex Medical Corp filed Critical Altarex Medical Corp
Application granted granted Critical
Publication of ATE290879T1 publication Critical patent/ATE290879T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
AT00957617T 1999-08-18 2000-08-18 Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung ATE290879T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14949299P 1999-08-18 1999-08-18
US16471499P 1999-11-11 1999-11-11
PCT/US2000/022890 WO2001012217A1 (en) 1999-08-18 2000-08-18 Therapeutic antibody against muc-1 antigen and methods for their use

Publications (1)

Publication Number Publication Date
ATE290879T1 true ATE290879T1 (de) 2005-04-15

Family

ID=26846783

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00957617T ATE290879T1 (de) 1999-08-18 2000-08-18 Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung

Country Status (7)

Country Link
EP (1) EP1204423B1 (enExample)
JP (2) JP2003519096A (enExample)
AT (1) ATE290879T1 (enExample)
AU (1) AU782569B2 (enExample)
DE (1) DE60018761T2 (enExample)
ES (1) ES2239032T3 (enExample)
WO (1) WO2001012217A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8038994B2 (en) 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
WO2002058450A2 (en) 2000-12-22 2002-08-01 Dana-Faber Cancer Institute, Inc. Regulation of cell growth by muc1
US6627664B2 (en) * 2001-01-30 2003-09-30 Altachem Pharma Ltd. Perylenequinones for use as sonosensitizers
US20040110846A1 (en) * 2001-01-30 2004-06-10 Beatrice Leveugle Perylenequinones for use with immunotherapy agents
ES2424131T3 (es) 2001-03-27 2013-09-27 Oncothyreon Inc. Vacuna para modular respuestas inmunitarias entre T1 y T2
AU2002358246B2 (en) * 2001-10-26 2008-02-28 Oncoquest Pharmaceuticals Inc. Combination therapy for treating disease
CN100356984C (zh) * 2002-01-24 2007-12-26 巴内斯－朱威胥医院 整联蛋白靶向的影像剂
DE10256900A1 (de) 2002-11-29 2004-06-24 Nemod Immuntherapie Ag Tumorspezifische Erkennungsmoleküle
DE10303664A1 (de) * 2003-01-23 2004-08-12 Nemod Immuntherapie Ag Erkennungsmoleküle zur Behandlung und Detektion von Tumoren
WO2005042573A1 (en) 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
TW201204410A (en) 2004-04-01 2012-02-01 Oncothyreon Inc Mucinous glycoprotein (MUC-1) vaccine
EP1848804B1 (en) * 2005-01-28 2011-10-05 Ramot at Tel Aviv University, Ltd. Anti-muc1 alpha beta antibodies
PT2366400E (pt) 2005-06-28 2016-02-02 Oncothyreon Inc Método de tratamento de doentes com uma vacina à base de glicoproteína mucinosa (muc-1)
US8506931B2 (en) 2005-08-10 2013-08-13 Quest Pharmatech Inc. Perylenequinone derivatives and uses thereof
US8454991B2 (en) 2006-07-24 2013-06-04 Quest Pharmatech Inc. Method and device for photodynamic therapy
WO2008028686A2 (en) 2006-09-10 2008-03-13 Glycotope Gmbh Use of human cells of myeloid leukaemia origin for expression of antibodies
PL1920781T3 (pl) 2006-11-10 2015-06-30 Glycotope Gmbh Kompozycje zawierające core-1-dodatnie mikroorganizmy i ich zastosowanie w leczeniu lub profilaktyce nowotworów
WO2008097844A2 (en) 2007-02-02 2008-08-14 Dana -Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins
WO2008097840A2 (en) 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
CA2741798A1 (en) 2008-10-28 2010-05-06 Shionogi & Co., Ltd. Anti-muc1 antibody
EP2281844A1 (en) 2009-07-31 2011-02-09 Glycotope GmbH MUC 1 antibodies
WO2011135869A1 (ja) 2010-04-28 2011-11-03 塩野義製薬株式会社 新規なｍｕｃ１抗体
JP2014518841A (ja) 2011-02-24 2014-08-07 オンコシレオン インク． アジュバントを備えたｍｕｃ１ベースのグリコリポペプチドワクチン
EP2748302B1 (en) 2011-08-22 2018-08-15 Glycotope GmbH Microorganisms carrying a tumor antigen
JP2017009287A (ja) * 2013-11-11 2017-01-12 東ソー株式会社 前立腺癌と前立腺肥大症との識別方法
JP6476170B2 (ja) 2014-04-28 2019-03-06 医化学創薬株式会社 抗ｍｕｃ１抗体又はその抗原結合性断片及びその用途
US20190343953A1 (en) * 2017-01-27 2019-11-14 Glycotope Gmbh Anti-cancer treatments with an anti-muc1 antibody and an erbb inhibitor
EP3794042B1 (en) 2018-05-18 2024-03-27 Daiichi Sankyo Co., Ltd. Anti-muc1- exatecan antibody-drug conjugate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993020841A1 (en) * 1992-04-13 1993-10-28 Dana-Farber Cancer Institute, Inc. Antibodies specific for carcinoma-associated antigens
FI950062A7 (fi) * 1992-07-06 1995-01-05 Biomira Inc Proteiinien foroaktivaatio konjugaatiotarkoituksia varten
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
DE19534630A1 (de) * 1995-09-18 1997-03-20 Max Delbrueck Centrum Monoklonale Antikörper gegen epitheliales Muzin (MUC1)
WO1997042973A1 (en) * 1996-05-15 1997-11-20 Altarex, Corp. Method and composition for reconforming multi-epitopic antigens to initiate an immune response
AU6017198A (en) * 1997-01-10 1998-08-25 Altarex Corp. Substituted perylenequinones for use in photodynamic therapy
EP1056472A2 (en) * 1998-02-13 2000-12-06 BASTERT, Gunter, Prof.Dr.med.Dr.h.c. Specific antibodies against mammary tumor-associated mucin, method for production and use

Also Published As

Publication number Publication date
AU6921100A (en) 2001-03-13
JP2003519096A (ja) 2003-06-17
WO2001012217A1 (en) 2001-02-22
DE60018761T2 (de) 2006-02-02
EP1204423A1 (en) 2002-05-15
AU782569B2 (en) 2005-08-11
JP2012046518A (ja) 2012-03-08
EP1204423B1 (en) 2005-03-16
WO2001012217A9 (en) 2002-06-27
ES2239032T3 (es) 2005-09-16
DE60018761D1 (de) 2005-04-21

Similar Documents

Publication Publication Date Title
DE60018761D1 (de) Therapeutische antikörper gegen das muc-1 antigen und verfahren zu deren verwendung
CY1120070T1 (el) Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους
NO331072B1 (no) Sammensetning som omfatter et angiogenese inhiberende middel og et anti tumor-immunoterapeutisk middel samt anvendelser av det samme.
DK1383785T3 (da) Rekombinant tumorspecifikt antistof og anvendelse deraf
EP1572087A4 (en) ANTIBODY TO CANCERANT TMEFF2 AND ITS APPLICATIONS
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
IL139700A0 (en) Immunotherapeutic composition and method for the treatment of prostate cancer
DE69531679D1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
EP1355563A4 (en) METHODS FOR THE PREVENTION AND TREATMENT OF CANCER USING ANTI-C3B(i) ANTIBODIES
ATE255906T1 (de) Antikörper gegen cd40
WO2003072036A3 (en) Treatment methods using anti-cd22 antibodies
DE69703121D1 (de) Verfahren und zusammensetzungen zur verhinderung von entzündungen und angiogenese enthaltend säugetieren cd97 alpha untereinheit
WO2004010947A3 (en) Humanized antibodies against human 4-1bb
GB2384084A (en) Methods and apparatus for implementing financial transactions
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
DE60033455D1 (de) Menschlischer monoklonaler Antikörper gegen Ep-CAM und dessen Verwendung in Krebstherapie
DK1782070T3 (da) Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi
BR9612619A (pt) Método e composição para reconformar antígenos multiepitópicos para iniciar uma resposta imunológica
ATE490785T1 (de) Parathormon-antikörper und damit zusammenhängende verfahren
EP1558284A4 (en) THERAPY ASSOCIATING CLASS III ANTI-ACE MONOCLONAL ANTIBODIES WITH THERAPEUTIC AGENTS
EP1581096A4 (en) ANTIGEN PIPA AND BINDING ANTIBODIES THEREOF
TW200517124A (en) Fully human antibodies against human 4-1BB
WO2000074729A3 (en) Alpha or beta emitters to fragments in radioimmunotherapy
TR200103432T2 (tr) Engelleyici monoklonal VLA-1 antikoru ve enflamasyonlu hastalıkların tedavisinde kullanımı.
GB0102145D0 (en) Substances

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1204423

Country of ref document: EP

REN Ceased due to non-payment of the annual fee
EEWE Authorization for restitution